Can you take Nelarabine with Tuberculin purified protein derivative?
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- nelarabine
- tuberculin purified protein derivative
Drug interactions
Moderate drug interactions
Moderate:
tuberculin purified protein derivative nelarabine
Applies to: tuberculin purified protein derivative and nelarabine
If you are currently being treated or have recently been treated with nelarabine, you should let your doctor know before receiving tuberculin purified protein derivative. Depending on the dose and length of time you have been on nelarabine, you may have a reduced response to the skin test. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
7 potential interactions Applies to: 7 conditions, including Liver Disease, Hyperuricemia Secondary to Chemotherapy, Neurological Disorders, Renal Dysfunction, and History, Radiation Therapy.
History, Radiation Therapy
Major:
nelarabine
Nelarabine has a major potential interaction with History, Radiation Therapy.
Severe neurologic adverse reactions have been reported with the use of nelarabine. Neurotoxicity is the dose-limiting toxicity of nelarabine. Patients treated previously or concurrently with intrathecal chemotherapy or previously with craniospinal irradiation may be at increased risk for neurologic adverse events. Close monitoring for neurologic adverse reactions is strongly recommended, when using nelarabine and therapy should be discontinued for neurologic adverse reactions of NCI Common Toxicity Criteria Grade 2 or greater.
Hyperuricemia Secondary to Chemotherapy
Moderate:
nelarabine
Nelarabine has a moderate potential interaction with Hyperuricemia Secondary to Chemotherapy.
Patients receiving nelarabine should receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumor lysis syndrome. Consideration should be given to the use of allopurinol in patients at risk of hyperuricemia.
Liver Disease
Moderate:
nelarabine
Nelarabine has a moderate potential interaction with Liver Disease.
The influence of hepatic impairment on the pharmacokinetics of nelarabine has not been evaluated. Because the risk of adverse reactions to this drug may be greater in patients with severe hepatic impairment (total bilirubin greater than 3 times upper limit of normal), it is recommended to closely monitor patients with severe liver dysfunction when treated with nelarabine.
Neurological Disorders
Major:
nelarabine
Nelarabine has a major potential interaction with Neurological Disorders.
Severe neurologic adverse reactions have been reported with the use of nelarabine. Neurotoxicity is the dose-limiting toxicity of nelarabine. Patients treated previously or concurrently with intrathecal chemotherapy or previously with craniospinal irradiation may be at increased risk for neurologic adverse events. Close monitoring for neurologic adverse reactions is strongly recommended, when using nelarabine and therapy should be discontinued for neurologic adverse reactions of NCI Common Toxicity Criteria Grade 2 or greater.
Renal Dysfunction
Moderate:
nelarabine
Nelarabine has a moderate potential interaction with Renal Dysfunction.
Nelarabine has not been studied in patients with renal dysfunction. There are insufficient data to support a dose recommendation for patients with a CrCl less than 50 mL/min. Because the risk of adverse reactions to this drug may be greater in patients with moderate (CrCl 30 to 50 mL/min) or severe (CrCl less than 30 mL/min) renal impairment, these patients should be closely monitored for toxicities if treated with this drug.
Tumor Lysis Syndrome
Moderate:
nelarabine
Nelarabine has a moderate potential interaction with Tumor Lysis Syndrome.
Patients receiving nelarabine should receive intravenous hydration according to standard medical practice for the management of hyperuricemia in patients at risk for tumor lysis syndrome. Consideration should be given to the use of allopurinol in patients at risk of hyperuricemia.
Vaccination
Major:
nelarabine
Nelarabine has a major potential interaction with Vaccination.
Immunocompromised patients receiving nelarabine should avoid receiving live vaccines.
Report options
More resources
nelarabine
A total of 338 drugs are known to interact with nelarabine.
- Nelarabine is in the drug class antimetabolites.
- Nelarabine is used to treat the following conditions:
tuberculin purified protein derivative
A total of 306 drugs are known to interact with tuberculin purified protein derivative.
- Tuberculin purified protein derivative is in the drug class in vivo diagnostic biologicals.
- Tuberculin purified protein derivative is used to treat Diagnosis and Investigation.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.